Table 3. Vaccine trials recruiting in the most affected countries during the Ebola virus disease outbreak in west Africa.

	Trial design	Research question (PICO model)	Registration number (declared status as of November, 2016)
rVSV ZEBOV
Ebola ça suffit!	Open label, cluster randomised, ring vaccination	Participants include contacts of confirmed EVD patients; intervention with immediate vaccination with rVSV ZEBOV; comparison with delayed (day 21) vaccination; outcome measured as safety and efficacy	Registered as PACTR201503001057193 (interim results available124)
Ebola ça suffit!	Open label, single arm	Participants include adult front-line workers; intervention with immediate vaccination with rVSV ZEBOV; comparison with delayed (day 21) vaccination; outcome measured as safety and efficacy	Registered as PACTR201503001057193 (closed to recruitment, follow up complete125)
STRIVE	Open label, randomised, with two substudies	Participants include adult front-line workers; intervention with immediate vaccination with vVSV ΔG ZEBOV; comparison with delayed (18–24 weeks) vaccination; outcomes measured as safety, efficacy, and immunogenicity	Registered as NCT02378753, PACTR201502001037220 (ongoing but not recruiting)
Multiple
PREVAC	Double-blind RCT	Participants include children and adults; intervention with immediate vaccination with rVSV-ZEBOV (with or without rVSV boost) or Ad26.ZEBOV + MVA-BN-Filo boost; comparison with placebo; outcomes measured as safety and immunogenicity	Registered as NCT02876328 (not yet open for recruitment)
PREVAIL	Double-blind RCT	Participants include adults with Ebola virus infection; intervention with immediate vaccination with VSVG-ZEBOV or ChAd3-EBO Z; comparison with placebo; outcomes measured as safety and immunogenicity	Registered as NCT02344407 (ongoing, but not recruiting, no results available)
Ad5-EBOV
Ad5-EBOV	Double-blind RCT	Participants include healthy adults aged 18–50 years in Sierra Leone; intervention with high dose, or low dose immediate vaccination with Ad5-EBOV; comparison with placebo; outcome measured as safety and immunogenicity	Registered as NCT02575456, PACTR201509001259869 (completed, no results available)
Ad26. ZEBOV + MVA-BN-Filo
EBOVAC	Open label, single arm, followed by double-blind RCT	Participants include healthy adults and children in Sierra Leone; intervention with immediate vaccination with Ad26-ZEBOV and with MVA-BN-Filo boost; comparison with placebo (meningococcal vaccine during immediate vaccination) during the second stage of the RCT; outcome measured as safety, immunogenicity, and efficacy	Registered as NCT02509494, PACTR201506001147964 (recruiting)

EVD=Ebola virus disease. PICO=participant, intervention, comparison, outcome. RCT=randomised controlled trial.